Comparative Effect of Intravenous Ketamine and Electroconvulsive Therapy in Major Depression: A Randomized Controlled Trial

Document Type : Original Article

Authors
Gholamreza Kheirabadi 1
Maryam Vafaie 1
Dorna Kheirabadi 2
Zahra Mirlouhi 1
Rasam Hajiannasab 3
1 Department of Psychiatry, School of Medicine, Behavioral Sciences Research Centre, Isfahan University of Medical Sciences, Isfahan, Iran
2 Department of psychiatry, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
3 School of Medicine, Azad University of Iran, Najafabad Unite, Najafabad, Iran
Abstract
Background: Achieving a rapid onset and durable methods of treatment for major depressive disorders is an issue pursuing in psychiatry. This study was designed to assess the therapeutic efficacy of intravenous (IV) ketamine injection in controlling depressive symptoms in comparison with electroconvulsive therapy (ECT) in major depressed disordered patients. Materials and Methods: Thirty-two patients over 18 years of age who were candidates for ECT were enrolled in the study. They were allocated into two groups using block design randomization. Sixteen patients received IV infusion of 0.5-mg/kg ketamine and 16 patients underwent a bitemporal ECT. To evaluate the changes in depression severity, researchers administered Hamilton Depression Rating Scale (HDRS) at baseline, before each treatment session, and four time points posttreatment (week 1 and months 1, 2, and 3). The Wechsler Memory Scale was used to evaluate the cognitive state of patients in week 1, month 1, and month 3 of the treatment. Results: The HDRS showed improvement in depressive symptoms in both the groups with no statistically significant difference. Cognitive state was more favorable (but not significant) in the ketamine group (P > 0.5). Conclusion: Treatment with IV ketamine in depressed people has the same antidepressant effects as ECT treatment without any memory deficiency.

Keywords

1.
Sadock BJ, Sadock VA, Ruiz P. Mood disorders. Synopsis of Psychiatry. 11th ed., Vol. 1. Philaledphia: Lippincott Williams & Wilkins; 2015. p. 347.  Back to cited text no. 1
    
2.
Jaso BA, Niciu MJ, Iadarola ND, Lally N, Richards EM, Park M, et al. Therapeutic modulation of glutamate receptors in major depressive disorder. Curr Neuropharmacol 2017;15:57-70.  Back to cited text no. 2
    
3.
Abdallah CG, Jiang L, De Feyter HM, Fasula M, Krystal JH, Rothman DL, et al. Glutamate metabolism in major depressive disorder. Am J Psychiatry 2014;171:1320-7.  Back to cited text no. 3
    
4.
Abdallah CG, Adams TG, Kelmendi B, Esterlis I, Sanacora G, Krystal JH, et al. Ketamine's mechanism of action: A path to rapid-acting antidepressants. Depress Anxiety 2016;33:689-97.  Back to cited text no. 4
    
5.
Sadock BJ, Sadock VA, Ruiz P. Brain stimulation methods. Synopsis of Psychiatry. 11th ed., Vol. 2. Philaledphia: Lippincott Williams & Wilkins; 2015. p. 1067.  Back to cited text no. 5
    
6.
Sadock BJ, Sadock VA, Ruiz P. Brain stimulation methods. Synopsis of Psychiatry. 11th ed., Vol. 2. Philaledphia: Lippincott Williams & Wilkins; 2015. p. 1071-2.  Back to cited text no. 6
    
7.
Zarate CA Jr., Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. Arandomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006;63:856-64.  Back to cited text no. 7
    
8.
Fond G, Loundou A, Rabu C, Macgregor A, Lançon C, Brittner M, et al. Ketamine administration in depressive disorders: A systematic review and meta-analysis. Psychopharmacology (Berl) 2014;231:3663-76.  Back to cited text no. 8
    
9.
Thase M. Mood disorders: Neurobiology. In: Sadock BJ, Sadock VA, Ruiz P, editors. Kaplan and Sadock's Comprehensive Textbook of Psychiatry. 9th ed., Vol. 1. Philadelphia: Lippincott Willams & Wilkins; 2009. p. 1670.  Back to cited text no. 9
    
10.
Aan Het Rot M, Collins KA, Murrough JW, Perez AM, Reich DL, Charney DS, et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry 2010;67:139-45.  Back to cited text no. 10
    
11.
Alberich S, Martínez-Cengotitabengoa M, López P, Zorrilla I, Núñez N, Vieta E, et al. Efficacy and safety of ketamine in bipolar depression: A systematic review. Rev Psiquiatr Salud Ment 2017;10:104-12.  Back to cited text no. 11
    
12.
Chilukuri H, Reddy NP, Pathapati RM, Manu AN, Jollu S, Shaik AB, et al. Acute antidepressant effects of intramuscular versus intravenous ketamine. Indian J Psychol Med 2014;36:71-6.  Back to cited text no. 12
[PUBMED]  [Full text]  
13.
Talbot JN, Geffert LM, Jorvig JE, Goldstein RI, Nielsen CL, Wolters NE, et al. Rapid and sustained antidepressant properties of an NMDA antagonist/monoamine reuptake inhibitor identified via transporter-based virtual screening. Pharmacol Biochem Behav 2016;150-151:22-30.  Back to cited text no. 13
    
14.
Maeng S, Zarate CA Jr. The role of glutamate in mood disorders: Results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects. Curr Psychiatry Rep 2007;9:467-74.  Back to cited text no. 14
    
15.
Ghasemi M, Kazemi MH, Yoosefi A, Ghasemi A, Paragomi P, Amini H, et al. Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder. Psychiatry Res 2014;215:355-61.  Back to cited text no. 15
    
16.
Kheirabadi GR, Vafaie M, Attari A. Intravenous ketamine therapy vs. electroconvulsive therapy in depressive cases. J Isfahan Med Sch 2012;29:1289-97.  Back to cited text no. 16
Advanced Biomedical Research
Volume 2019, April
April 2019
Pages 1-5